Nivolumab Extends Survival for Patients With the Most Common Lung Cancer - European Medical Journal

Nivolumab Extends Survival for Patients With the Most Common Lung Cancer

Oncology

Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC). Among patients with advanced disease that worsened after receiving platinum-based chemotherapy, those treated with nivolumab lived on average three months longer than those treated with docetaxel chemotherapy.

Presented at ASCO 2015, Chicago, IL by Professor Luis Paz-Ares, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>